NUP98 and prostate adenocarcinoma: While there is no information on the clinical/predictive utility of NUP98 in patients with PRAD, our results suggest it is one of the main drivers of early stage PRAD in the Hispanic population and, thus, a promising target for further studies exploring its usefulness as a biomarker of prognosis and therapy response.